CDK4 and neoplasm: Abemaciclib showed higher disease control with a median PFS of 7 months in a phase II trial enrolling advanced DD-LPS patients.30 We found four individuals with CDK4 tumor amplification in our study but there was either no correlation with CDK4 expression or with a better survival outcome.